Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Panacea Biotec Limited

Panacea Biotec is an innovation driven company focused on research and development, manufacturing, sales, distribution, and marketing of nutrition, vaccines, and pharmaceuticals.

msh id	COM:PANACEABIOTEC
symbol	PANACEABIO
name	Panacea Biotec Limited
homepage url	https://www.panaceabiotec.com
country	IN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	1.79K
crunchbase url	-
linkedin url	-
founders	-

market cap	102.32M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.16
growth cost of revenue	-0.16
growth depreciation and amortization	-0.1
growth ebitda	-13.87
growth ebitda ratio	-20.31
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.43
growth gross profit	-0.42
growth gross profit ratio	-0.17

COM:PANACEABIOTEC

Panacea Biotec

Last Close

414.00

22/11 09:00

Market Cap

8.60B

Beta: -

Volume Today

102.24K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	85.31M
cost of revenue	85.31M
depreciation and amortization	5.23M
ebitda	-372.94K
ebitda ratio	-0
eps	2.11
eps diluted	2.11
operating expenses	49.38M
operating income	-5.6M
operating income ratio	-0.07

accounts receivables	825.64K
capital expenditure	-4.9M
cash at beginning of period	6.03M
cash at end of period	4.77M
inventory	25.48M
working capital ttm	2.03B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-